The Library
A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer : correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints
Tools
Tools
Tools
Ferry, D. R., Deakin, M., Baddeley, J., Daryanani, S., Bramhall, S., Anderson, D. A., Wakelam, M. J. O., Doran, J., Pemberton, G., Young, Annie M., Buckels, J. and Kerr, D. J. (2000) A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer : correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. Annals of Oncology, 11 (9). pp. 1165-1170. doi:10.1023/A:1008303715515 ISSN 0923-7534.
Research output not available from this repository.
Request-a-Copy directly from author or use local Library Get it For Me service.
Official URL: http://dx.doi.org/10.1023/A:1008303715515
Abstract
Purpose: Primary objective was to determine response rate of patients with advanced pancreatic cancer to a novel lipoxy-genase and thromboxane A2 synthetase inhibitor (CV6504); secondary objectives included estimation of pharmacokinetics of CV6504, target-enzyme inhibition, safety and tolerance, quality of life and survival. Patients and methods: Thirty-one patients with advanced pancreatic cancer were planned to receive CV6504, 100 mg TDS, orally for three months, at which point CT scans were performed to assess therapeutic response rates. Steady state concentrations of CV6504 and thromboxane B2 (an indirect measure of thromboxane A2 synthetase (TA2S) inhibition) were made. Of the 31 patients entered into the study, 23 were considered fully evaluable for response. Results: The drug was well tolerated with few side effects; no partial or complete responses were seen, but 10 patients had stable disease at 3 months; quality of life was maintained during therapy; mean CV6504 steady state plasma concentrations of 14 ± 6 ng/ml resulting in 75 ± 18% inhibition of TA2S were achieved; median-survival time for all patients considered eligible for assessment of efficacy was 36.6 weeks after the initial dose of study medication. The actuarial one-year survival was approximately 25%. Conclusion: CV6504 inhibits its target enzyme in vivo, maintains stable disease in 32% of evaluable patients and is well tolerated.
| Item Type: | Journal Article | ||||
|---|---|---|---|---|---|
| Subjects: | R Medicine > R Medicine (General) | ||||
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Clinical Trials Unit Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||
| Journal or Publication Title: | Annals of Oncology | ||||
| Publisher: | Oxford University Press | ||||
| ISSN: | 0923-7534 | ||||
| Official Date: | 1 September 2000 | ||||
| Dates: |
|
||||
| Volume: | 11 | ||||
| Number: | 9 | ||||
| Page Range: | pp. 1165-1170 | ||||
| DOI: | 10.1023/A:1008303715515 | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Restricted or Subscription Access |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
